Immupharma (IMM) Stock Discussion | Share discussion

Immupharma

ImmuPharma plc, a drug discovery and development company, is engaged in the development of drugs based on peptide therapeutics to treat serious medical conditions.

Industry: Pharmaceuticals & Biotechnology

Ticker	Exchange	ISIN
$IMM	LSE AIM	GB0033711010

Recent news

Carnival Net Income dropped on 442% and Revenue dropped on 73.1%

Unisys Corp reports 4,465% Net Income growth in 2020 while 31.3% Revenue decline

Northamber Net Income surged on 1,523%

International Bus Mach Corp reports 40.7% Net Income decline in 2020 and 3.2 pp EBITDA Margin decline from 20.7% to 17.5%

Blue Prism Group plc revenue surged on 40% and EBITDA Margin surged on 28.9 pp from -78.3% to -49.4%

Tui Ag EBITDA dropped on 220% and Revenue dropped on 58.0%

Zytronic Net Income dropped on 111% and EBITDA Margin dropped on 15.0 pp from 20.6% to 5.6%

Image Scan Hldgs revenue surged on 47.3% and EBITDA Margin surged on 21.0 pp from -16.0% to 5.0%

Oxford Metrics Net Income dropped on 61.6% and Revenue dropped on 14.3%

I-Nexus Global Plc revenue dropped on 14.3%

Twit about IMM stock

Share your investment idea or question on Immupharma stock:

Latest twits on Immupharma (IMM)

No twits yet. Be the first to post!

Have a question about IMM? Ask and other investors will be eager to help you.

Have an idea about IMM? Share it with other investors.

Immupharma stock price chart

Immupharma financials

mln. £	FY2015

Revenue	0.076
EBITDA	0.000
Net income	0.000
CAPEX	0.000
Debt	0.000
Cash	0.000

About Immupharma

ImmuPharma plc, a drug discovery and development company, is engaged in the development of drugs based on peptide therapeutics to treat serious medical conditions. The company